Medtronic Balances a Class I Recall Against Fresh Pipeline Wins and a Looming MiniMed Deadline
Published on 10/04/2026 at 00:20 | Editorial boerse-global.de
Medtronic is navigating one of the more awkward stretches of its recent history: a top-severity safety action on an esophageal monitoring device, a string of regulatory clearances across its heart and vascular franchises, and a spinoff exchange offer that is now weeks away from expiring.
The stock finished Friday at EUR 76.72, down 0.3% on the day, giving the medical technology group a market value of EUR 97.94 billion.
FDA Slaps Highest Risk Label on Bravo CF
On September 15, the U.S. Food and Drug Administration classified the recall of Medtronic's Bravo CF capsule delivery system — run together with subsidiary Given Imaging — as a Class I recall, the agency's most serious designation. According to the FDA, use of the affected products can lead to severe injury or death.
As of August 10, 2026, 184 serious injuries had been reported in connection with the system. No fatalities have been linked to it, the agency said. The device, used to monitor pH levels in the esophagus, is being withdrawn from the market under the FDA's supervision.
Cardiac and Vascular Programs Rack Up Clearances
While the recall plays out, Medtronic's pipeline has been collecting wins. The FDA granted breakthrough device status to the company's IN.PACT BTK drug-coated balloon on September 30. To build out the clinical case, Medtronic plans a global randomized pivotal trial enrolling roughly 400 patients. The device is designed to treat vascular disease below the knee and remains in development, meaning it has not yet won approval or market clearance.
Should investors sell immediately? Or is it worth buying Medtronic?
Mapping software also cleared key hurdles: Affera Prism-2 secured both FDA approval and European CE marking. European reviewers additionally issued a CE certificate for the PulseSelect ProxBox adapter and its associated spacing-indicator software. Both technologies aim at more precise control during electrophysiology procedures.
On the surgical robotics side, the FDA cleared the LigaSure RAS Maryland instrument for use on the Hugo robotic surgery platform about two weeks ago. The shares have shed 5.0% since that green light.
Reimbursement Wins Set a 2028 Horizon
Further out, the American Medical Association approved new Category I CPT billing codes for two Medtronic systems: the Altaviva implantable tibial neuromodulation device and the Symplicity Spyral renal denervation system. The new codes replace the previous Category III designations and take effect in January 2028.
MiniMed Separation Nears Its Deadline
All of this unfolds against the backdrop of Medtronic's plan to separate its diabetes unit, MiniMed. The exchange offer, launched roughly three weeks ago, covers up to 225,361,295 MiniMed shares that can be swapped for Medtronic stock. Per a mandatory disclosure, the offer is set to expire on October 9, 2026, unless extended or terminated early. The shares have lost 2.2% since the spinoff process began.
Analyst Backing and a Recognition Nod
TD Cowen reaffirmed its "Buy" rating on Medtronic on Wednesday, according to media reports, with a price target of US$110. The vote of confidence lands as investors weigh how cleanly the company executes its strategic reshuffling.
Medtronic also earned a place on Fortune's 2026 "Change the World" list, recognized for its Touch Surgery surgical ecosystem and its Healthy Neighbor initiative.
The near-term task is twofold: close out the gastroenterology safety requirements without lasting damage, and move the newly cleared platforms steadily into clinical practice.
Ad
Medtronic Stock: New Analysis - 4 October
Fresh Medtronic information released. What's the impact for investors? Our latest independent report examines recent figures and market trends.
